Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of 177Lu-DOTA0-Tyr3-octreotate in neuroendocrine tumors
2009-012260-14Phase 2Completed
- Sponsor
- Department of Endocrine Oncology, Uppsala University Hospital
- Start
- Oct 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), sponsored by Department of Endocrine Oncology, Uppsala University Hospital. Primary endpoint: Radiological response rate. Started Oct 2009; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2009-012260-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012260-14.